A team of researchers from the Rice Biotech Launch Pad at Rice University has developed an implantable "cytokine factory" that safely triggers potent immune responses against hard-to-treat cancers, ...

A team of researchers from the Rice Biotech Launch Pad at Rice University has developed an implantable "cytokine factory" ...

Researchers examined the risk for serious infection among patients with atopic dermatitis treated with Janus kinase inhibitors vs Th2 cytokine inhibitors.

Regarding immunomodulatory strategies, emerging approaches such as multi-target cytokine inhibitors (e.g., simultaneously targeting IL-1β and TNF-α), immune cell-targeted therapies (e.g., promoting M2 ...

Specifically, based on its mechanism, “IL-23 is viewed by some as the overarching master cytokine in the psoriasis ... that early use of high-dose IL-23 inhibitors might “induce long-term ...

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.

Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland ...

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized oncology ... with hypotheses ranging from antigen mimicry to cytokine dysregulation and microbiome alterations.